TLR9 and neoplasm: STAT3 inhibition and TLR9 immunostimulation disrupt the tolerogenic effects of the tumor microenvironment and thereby lead to potent antitumor immune responses in a variety of preclinical tumor models in mice [87,89,90,91,92].